Scholar Rock received FDA approval for ISEMBYLD, the first muscle-targeted therapy for spinal muscular atrophy (SMA), aimed at patients aged two and older already on other treatments. The drug is priced at $11,659 per vial and has earned a Rare Pediatric Disease Priority Review Voucher. Following this milestone, Jefferies raised Scholar Rock's price target from $57 to $65, reflecting optimism about the company's growth potential. The stock traded at $51.85 with a market cap of about $6.21 billion at the time of the update.
Scholar Rock's recent FDA approval news is presented here with Pluang's health sector market data as of Sep 15, 2026 19:14 WIB: Among 91 priced US health stocks, 28 rose and 59 fell. Notable movers include AMWL at USD 13.66 with a -1.51% change, HRTX at USD 0.32 with a +1.49% change, and CNC at USD 68.40 with a -1.41% change.
Parex Resources announced its Q3 2026 average production reached 83,259 barrels of oil equivalent per day, driven by exploration success and a partnership with Ecopetrol. The company reaffirmed its H2 2026 production guidance of 82,000 to 91,000 boe/...
EnergyLIB is entering a new growth phase following a proposed strategic investment by Nasdaq-listed Cheche Group in its residential solar-plus-storage business, Long Way Fortune. This investment supports Cheche Group's expansion into the global resid...
Copa Holdings announced preliminary passenger traffic data for September 2026, showing a 17.1% increase in revenue passenger miles (RPM) to 2,674.4 million and a 15.7% rise in available seat miles (ASM) to 3,041.0 million compared to September 2025. ...
Bitdeer Technologies Group has issued a notice asking journalists and readers to disregard a previously released news statement about Bitdeer AI securing 60MW at its Cyberjaya, Malaysia facility and reaching 95% of its 350MW target capacity. This ret...
SpaceX is expanding its AI infrastructure to support its rocket launches, Starlink satellite network, and future AI growth plans. Analysts show mixed but generally positive sentiment, with Morgan Stanley maintaining a Buy rating and a $300 price targ...
